IN THE CLAIMS:

Jul 6'

23. (Twice Amended) A method of producing antibodies to an antigen of human immunodeficiency virus type 1 (HIV-1), said method comprising:

(a) providing an antigen of HIV-1, wherein said antigen is the expression product of a host transformed with a vector containing a (nucleic acid fragment) of plasmid λ -J19, and wherein said nucleic acid fragment [comprises the restriction site HindIII at about coordinate 9250, the restriction site SacI at about coordinate 9200, and the restriction site BglII at about coordinate 9150] extends from the restriction site [KpnI] at about coordinate 6100 to the restriction site [BglII] at about coordinate 9150 of plasmid λ -J19;

FNV

- (b) raising antibodies against said antigen, and
- (c) recovering said antibodies.

J8

- 32. (Amended) A method of producing antibodies to an antigen of human immunodeficiency virus type 1 (HIV-1), said method comprising:
 - (a) providing an antigen of HIV-1, wherein said antigen is the expression product of a host transformed with a vector containing a nucleic acid fragment of plasmid λ -J19, and wherein said (nucleic acid fragment) [comprises the restriction site HindIII at about coordinate 9250, the restriction site SacI at about coordinate 9200, the restriction site BglII at about

LAW OFFICES
FINNEGAN, HENDERSON
FARABOW, CARRETT
& DUNNER
1300 I STREET, N. W.
WASHINGTON, DC 20005
1-202-408-4000

**

coordinate 9150, the restriction site BgIII at about coordinate 8750, and the restriction site KpnI at about coordinate 8700] extends from the restriction site KpnI at about coordinate 3500 to the restriction site BgIII at about coordinate 6500 of plasmid λ -J19,

- (b) raising andibodies against said antigen, and
- (c) recovering said antibodies.
- 33. (Amended) A method of producing antibodies to an antigen of human immunodeficiency virus type 1 (HIV-1), said method comprising:
- (a) providing an antigen of HIV-1, wherein said antigen is the expression product of a host transformed with a vector containing a nucleic acid fragment of plasmid λ-J19, and wherein said nucleic acid fragment [comprises the restriction site HindIII at about coordinate 9250, the restriction site SacI at about coordinate 9200, the restriction site BglII at about coordinate 9150, the restriction site BglII at about coordinate 8750, the restriction site KpnI at about coordinate 8700, the restriction site XhoI at about coordinate 8600, the restriction site BamHI at about coordinate 8150, the restriction site HindIII at about coordinate 7850, and the restriction site BglII at about coordinate 7600] extends from the restriction site PstI at about coordinate 800 to the restriction site KpnI at about coordinate 3500 of plasmid λ-J19,
 - (b) raising antibodies against said antigen, and
 - (c) recovering said antibodies.

6 A CO

LAW OFFICES
FINNEGAN, HENDERSON
FARABOW, CARRETT

8 DUNNER
1300 I STREET, N. W.
WASHINGTON, DC 20005
1-202-408-4000